Yakult Honsha gained exclusive commercialization rights to GPC Biotech’s satraplatin in Japan for an upfront payment of 1.2 billion yen or $10 million.
According to the license transaction, Yakult will take the lead in the final development of the drug in Japan. Satraplatin has shown statistically significant improvement in progression-free survival in Phase III investigations as a treatment for hormone refractory prostate cancer and its NDA is scheduled to be reviewed by an advisory committee on July 24.
In addition to the upfront fee, Yakult will also make payments based on the achievement of certain regulatory filing and approval milestones. GPC Biotech will also receive a minimum of 21% royalties on sales in Japan.